Skip to content
BOE-A-2026-12611 ·11 June 2026 ·Royal Decree Medium impact
Administrative

Pharmaceutical companies: 3 months to implement electronic drug registration system

Royal Decree 468/2026 amends RD 1345/2007 to require electronic registration for industrially manufactured medicinal products for human use. A new additional provision 7 is introduced, establishing a three-month implementation period from the date of entry into force. This change aims to modernise the control system and improve the traceability of pharmaceutical products (Art. 81.1, 84-86, additional provision 7).

In 2 key points

  1. An additional provision 7 is added for the electronic registration of medicinal products (art. 81.1, 84-86, disp. ad. 7)
  2. A 3-month deadline to adapt the registration system from the date of entry into force (art. 81.1, 84-86, disp. ad. 7)

How it affects those involved

For pharmaceutical companies, this entails an obligation to adapt their registration systems to an electronic format, with the risk of fines for non-compliance within the deadline. Health authorities will benefit from enhanced traceability. Advisors must inform clients of the new obligation and the relevant deadlines. Management system providers must prepare to integrate the new regulation.

Lifecycle

2026-06-11PublishedPublished in the BOE
2026-06-12Into forceComes into force (fecha_vigencia (indice oficial del BOE))
Official text Based on BOE data (boe.es). Information, not advice.

Does this provision affect you?

The administrative team reviews your specific situation.

Talk to the administrative team
This analysis is informational only and does not constitute legal advice or create a client-adviser relationship. BM Consulting.
Email
Contact